KR890002633B1 - B형간염 바이러스의 ad, ay형 표면 항원에 대한 모노클로날 항체의 제조방법 - Google Patents
B형간염 바이러스의 ad, ay형 표면 항원에 대한 모노클로날 항체의 제조방법 Download PDFInfo
- Publication number
- KR890002633B1 KR890002633B1 KR1019860001927A KR860001927A KR890002633B1 KR 890002633 B1 KR890002633 B1 KR 890002633B1 KR 1019860001927 A KR1019860001927 A KR 1019860001927A KR 860001927 A KR860001927 A KR 860001927A KR 890002633 B1 KR890002633 B1 KR 890002633B1
- Authority
- KR
- South Korea
- Prior art keywords
- hepatitis
- antibody
- surface antigen
- monoclonal antibody
- virus
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims description 49
- 108091007433 antigens Proteins 0.000 title claims description 49
- 102000036639 antigens Human genes 0.000 title claims description 49
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 241000700739 Hepadnaviridae Species 0.000 title 1
- 238000000034 method Methods 0.000 claims description 31
- 241000700721 Hepatitis B virus Species 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 238000003018 immunoassay Methods 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 238000001962 electrophoresis Methods 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000003119 immunoblot Methods 0.000 claims description 2
- 230000001235 sensitizing effect Effects 0.000 claims description 2
- 206010070834 Sensitisation Diseases 0.000 claims 2
- 230000008313 sensitization Effects 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 239000000020 Nitrocellulose Substances 0.000 description 8
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 229940079938 nitrocellulose Drugs 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000006454 hepatitis Diseases 0.000 description 7
- 231100000283 hepatitis Toxicity 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000019750 Crude protein Nutrition 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WONRDHPFOHAWOG-UHFFFAOYSA-N 2-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1 WONRDHPFOHAWOG-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101000940468 Drosophila melanogaster COP9 signalosome complex subunit 2 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710132772 Peroxidase 1 Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003657 drainage water Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (2)
- B형간염 바이러스의 표면 항원(ad및 ay형)중 프리에스 (pre-s) 부위에 대한 모노클로날 항체의 제조에 있어서, 전기 영동법에 의해 얻어진 프리에스 밴드를 겔로부터 용출시키고 용출된 프리에스 단백질을 쥐에 감작시킨 다을, 공지의 방법으로 하미브리도마를 생산하고 이들중 프리에스 부위에 특이한 반응을 나타내는 클론을 공지의 임뮤노블러팅 기술, 효소 면역 측정법(EIA)을 이용하여 프리에스 부위에 대한 모노클로날 항체를 생산하는 것을 특징으로 하는 모노클로날 항체의 제조방법.
- 제1항에 있어서, B형간염 바이러스 표면 항원으로 쥐를 감작시킬 때 정제된 ad, ay형 표면 항원의 조합을 ad로 1차 감작시키고 ay로 2차 감작시키거나, ay로 1차 감작시키고 ad로 2차 감작시키거나, ad로 1차.2차 감착시키거나 ay로 1차.2차 감착시켜서 서브타입 ad, ay 또는 ad 및 ay 공통에 대해 특이성을 갖는 항체 생산 세포를 취득함을 특징으로 하는 모노클로날 항체의 제조방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019860001927A KR890002633B1 (ko) | 1986-03-17 | 1986-03-17 | B형간염 바이러스의 ad, ay형 표면 항원에 대한 모노클로날 항체의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019860001927A KR890002633B1 (ko) | 1986-03-17 | 1986-03-17 | B형간염 바이러스의 ad, ay형 표면 항원에 대한 모노클로날 항체의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR870008589A KR870008589A (ko) | 1987-10-19 |
KR890002633B1 true KR890002633B1 (ko) | 1989-07-21 |
Family
ID=19248893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019860001927A KR890002633B1 (ko) | 1986-03-17 | 1986-03-17 | B형간염 바이러스의 ad, ay형 표면 항원에 대한 모노클로날 항체의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR890002633B1 (ko) |
-
1986
- 1986-03-17 KR KR1019860001927A patent/KR890002633B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR870008589A (ko) | 1987-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4595654A (en) | Method for detecting immune complexes in serum | |
US4828981A (en) | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents | |
US6326159B1 (en) | Receptors for immune complexes | |
US20090246795A1 (en) | Immunoassay device and method | |
CA2008304C (en) | Assay for bone alkaline phosphatase | |
US4665018A (en) | Methods and test kit for diagnosing/monitoring cancer in humans | |
CZ283072B6 (cs) | Způsob stanovení koncentrace různých látek | |
JP2006522736A (ja) | アシアロα1−酸性糖タンパクに対するモノクロナール抗体、モノクロナール抗体からなる免疫クロマトグラフィ用帯状片及びこの免疫クロマトグラフィ用帯状片を用いる肝疾患診断法 | |
KR890002633B1 (ko) | B형간염 바이러스의 ad, ay형 표면 항원에 대한 모노클로날 항체의 제조방법 | |
US4816390A (en) | Immunochemical assay of carcinoembryonic antigen and reagent therefor | |
CA2281262C (en) | Anti-human medullasin monoclonal antibody, process for producing the same and immunoassay using the same | |
EP0308242B1 (en) | Agglutination assay | |
Keir et al. | Nitrocellulose immunofixation following agarose electrophoresis in the study of immunoglobulin G subgroups in unconcentrated cerebrospinal fluid | |
Nomura et al. | A pitfall in two-site sandwich ‘one-step’immunoassay with monoclonal antibodies for the determination of human alpha-fetoprotein | |
EP3306319B1 (en) | Test object detection method, and immunoassay instrument and monoclonal antibody for same | |
JP3015121B2 (ja) | 非A1c糖化ヘモグロビンに対するモノクローナル抗体 | |
US5298397A (en) | Method of assaying d-vanillylmandelic acid | |
JP2009508087A (ja) | モノクローナル抗体試薬 | |
CA1291422C (en) | Immunometric assay for high molecular weight carcinoembryonic antigen | |
EP0409883B1 (en) | Monoclonal antibody to enteroviruses | |
WO1992019755A1 (en) | MONOCLONAL ANTIBODY AGAINST HUMAN β2-GLYCOPROTEIN I AND USE THEREOF | |
KR940002521B1 (ko) | 인체 프로릴 4-히드록시라아제의 정량 방법 | |
EP0138946B1 (en) | Methods for monitoring the status of cancer in humans | |
CN114181909B (zh) | 一种杂交瘤细胞株及其单克隆抗体与试剂盒 | |
US5179008A (en) | Hybridoma and monoclonal antibody to FHAP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19860317 |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19890124 Patent event code: PE09021S01D |
|
G160 | Decision to publish patent application | ||
PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19890621 |
|
O035 | Opposition [patent]: request for opposition |
Free format text: OPPOSITION NUMBER: 001989000386; OPPOSITION DATE: 19890904 |
|
PO0301 | Opposition |
Comment text: Request for Opposition Patent event code: PO03011R01D Patent event date: 19890904 Opposition date: 19890904 Opposition identifier: 001989000386 |
|
PC1902 | Submission of document of abandonment before decision of registration | ||
SUBM | Surrender of laid-open application requested |